The CTC had excellent representation at EHA 23 in Stockholm this year, with eight abstracts from four trials presented (listed below).
It was a bumper year for UKALL14, the UK’s front line study for adults with acute lymphoblastic leukaemia, which had two talks and three posters accepted for presentation. Four used data generated by translational projects from trial and the fifth focused on the outcomes of transplanted patients post-relapse.
Quality of life analyses were presented for the Watch and Wait study, a trial looking at Rituximab vs watchful waiting in newly diagnosed Follicular lymphoma patients.
A poster presented chemotherapy-related toxicity rates in overweight patients treated on the RATHL trial; overweight patients were not dose capped on this trial, but this did not cause them to experience an excessive amount of toxicity.
Finally, the CTC’s haematology clinical fellow Dr Beth Phillips (pictured) discussed the results of the R-CODOX-M/IVAC trial for high-risk Diffuse Large B-cell lymphoma and Burkitt’s lymphoma, as well as presenting outcomes for high-risk subtypes.
R-CODOX-M/IVAC oral
E. Phillips, et al.
Favourable outcomes with R-CODOX-M/R-IVAC across all subgroups of aggressive high grade B-cell lymphoma: pathology and updated survival results from a phase 2 NCRI/LLR trial
UKALL14 orals
R. Burt, et al.
Mesenchymal stromal cells protect acute lymphoblastic leukaemia cells from cytarabine induced apoptosis by transfer of mitochondria via tunnelling nanotubes in a treatment resistant niche model
A. Moorman, et al.
Comprehensive screening of B-other adult ALL patients treated on UKALL14 estimates frequency and prognostic impact of gene alterations and identifies JAK-STAT abnormalities as markers of poor outcome
UKALL14 posters
R. Mitchell, et al.
Prognostic value of IKZF1 deletions on the UKALL14 trial: significant role of BCR-ABL1 status
A. Castleton, et al.
Characteristics and outcomes of adults with acute lymphoblastic leukaemia relapsing post-allogeneic haematopoietic cell transplantation in the prospective UKALL14 trial
K. Bailey, et al.
Re-thinking the prognostic relevance of a CD20 expression cut off of 20% in acute lymphoblastic leukaemia: initial results from the UKALL14 trial
RATHL poster
B. Merron, et al.
Overweight lymphoma patients treated by actual body weight had no excess of chemotherapy toxicity: experience from two large trials
Watch & Wait poster
M. Marzolini, et al.
Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting: phase 3 randomised international study
Photo: Beth Phillips presenting at the conference, by Amy Kirkwood